nach oben

Erschienen in:

01.03.2014 | Article

TCF7L2 in mouse pancreatic beta cells plays a crucial role in glucose homeostasis by regulating beta cell mass

verfasst von: Iseki Takamoto, Naoto Kubota, Keizo Nakaya, Katsuyoshi Kumagai, Shinji Hashimoto, Tetsuya Kubota, Mariko Inoue, Eiji Kajiwara, Hisayuki Katsuyama, Atsushi Obata, Yoshitaka Sakurai, Masahiko Iwamoto, Tadahiro Kitamura, Kohjiro Ueki, Takashi Kadowaki

Erschienen in: Diabetologia | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Common genetic variations of the transcription factor 7-like 2 gene (encoded by TCF7L2), one of the T cell factor/lymphoid enhancer-binding factor transcription factors for the converging wingless-type MMTV integration site family (Wnt)/β-catenin signalling pathway, are known to be associated with type 2 diabetes. Individuals with at-risk alleles of TCF7L2 exhibit impaired insulin secretion. Although previous studies using animal models have revealed the existence of a relationship between the Wnt/β-catenin signalling pathway and glucose homeostasis, it remains unclear whether TCF7L2 in the pancreatic beta cells might be causally involved in insulin secretion in vivo. In this study, we investigated the role of TCF7L2 expressed in the pancreatic beta cells in glucose homeostasis.

Methods

Three independent groups of genetically engineered mice (DN mice) were generated, in which expression of the dominant-negative form of Tcf7l2 was driven under a rat insulin promoter. Phenotypes of both adult and newborn mice were evaluated. The levels of genes and proteins expressed in isolated islets were determined by reverse transcription-quantitative PCR and western blot analysis, respectively.

Results

Adult DN mice showed impaired glucose tolerance and decreased insulin secretion in both oral and intraperitoneal glucose tolerance tests. Marked reduction of the beta cell area and whole-pancreas insulin content was observed in both the adult and newborn DN mice. Islets from the DN mice showed decreased gene expressions of Ccnd1, Ccnd2, Irs1, Irs2, Ins1, Ins2 and Mafa, consistent with the deleterious effects of the dominant-negative form of Tcf7l2 on beta cell proliferation and insulin production.

Conclusions/interpretation

TCF7L2 expressed in the pancreatic beta cells plays a crucial role in glucose metabolism through regulation of the beta cell mass.

Nur mit Berechtigung zugänglich

Kadowaki T, Miyake Y, Hagura R et al (1984) Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia 26:44–49PubMedCrossRef

Kadowaki T (2000) Insights into insulin resistance and type 2 diabetes from knockout mouse models. J Clin Invest 106:459–465PubMedCentralPubMedCrossRef

Grant SF, Thorleifsson G, Reynisdottir I et al (2006) Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 38:320–323PubMedCrossRef

Liu Z, Habener JF (2010) Wnt signaling in pancreatic islets. Adv Exp Med Biol 654:391–419PubMedCrossRef

Horikoshi M, Hara K, Ito C, Nagai R, Froguel P, Kadowaki T (2007) A genetic variation of the transcription factor 7-like 2 gene is associated with risk of type 2 diabetes in the Japanese population. Diabetologia 50:747–751PubMedCrossRef

Miyake K, Horikawa Y, Hara K et al (2008) Association of TCF7L2 polymorphisms with susceptibility to type 2 diabetes in 4,087 Japanese subjects. J Hum Genet 53:174–180PubMedCrossRef

Yamauchi T, Hara K, Maeda S et al (2010) A genome-wide association study in the Japanese population identifies susceptibility loci for type 2 diabetes at UBE2E2 and C2CD4A-C2CD4B. Nat Genet 42:864–868PubMedCrossRef

Florez JC, Jablonski KA, Bayley N et al (2006) TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 355:241–250PubMedCentralPubMedCrossRef

Saxena R, Gianniny L, Burtt NP et al (2006) Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes 55:2890–2895PubMedCrossRef

10.

Lyssenko V, Lupi R, Marchetti P et al (2007) Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 117:2155–2163PubMedCentralPubMedCrossRef

11.

Villareal DT, Robertson H, Bell GI et al (2010) TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes 59:479–485PubMedCrossRef

12.

Arce L, Yokoyama NN, Waterman ML (2006) Diversity of LEF/TCF action in development and disease. Oncogene 25:7492–7504PubMedCrossRef

13.

Hoppler S, Kavanagh CL (2007) Wnt signalling: variety at the core. J Cell Sci 120:385–393PubMedCrossRef

14.

Welters HJ, Kulkarni RN (2008) Wnt signaling: relevance to beta-cell biology and diabetes. Trends Endocrinol Metab 19:349–355PubMedCrossRef

15.

Murtaugh LC (2008) The what, where, when and how of Wnt/beta-catenin signaling in pancreas development. Organogenesis 4:81–86PubMedCentralPubMedCrossRef

16.

Jin T (2008) The WNT signalling pathway and diabetes mellitus. Diabetologia 51:1771–1780PubMedCrossRef

17.

Dabernat S, Secrest P, Peuchant E, Moreau-Gaudry F, Dubus P, Sarvetnick N (2009) Lack of β-catenin in early life induces abnormal glucose homeostasis in mice. Diabetologia 52:1608–1617PubMedCrossRef

18.

Korinek V, Barker N, Moerer P et al (1998) Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat Genet 19:379–383PubMedCrossRef

19.

Boj SF, van Es JH, Huch M et al (2012) Diabetes risk gene and Wnt effector Tcf7l2/TCF4 controls hepatic response to perinatal and adult metabolic demand. Cell 151:1595–1607PubMedCrossRef

20.

Vacik T, Lemke G (2011) Dominant-negative isoforms of Tcf/Lef proteins in development and disease. Cell Cycle 10:4199–4200PubMedCrossRef

21.

Vacik T, Stubbs JL, Lemke G (2011) A novel mechanism for the transcriptional regulation of Wnt signaling in development. Genes Dev 25:1783–1795PubMedCrossRef

22.

Nguyen H, Merrill BJ, Polak L et al (2009) Tcf3 and Tcf4 are essential for long-term homeostasis of skin epithelia. Nat Genet 41:1068–1075PubMedCentralPubMedCrossRef

23.

Terauchi Y, Takamoto I, Kubota N et al (2007) Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. J Clin Invest 117:246–257PubMedCentralPubMedCrossRef

24.

Kamei N, Tobe K, Suzuki R et al (2006) Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 281:26602–26614PubMedCrossRef

25.

Kubota N, Kubota T, Itoh S et al (2008) Dynamic functional relay between insulin receptor substrate 1 and 2 in hepatic insulin signaling during fasting and feeding. Cell Metab 8:49–64PubMedCrossRef

26.

Miyazaki J, Araki K, Yamato E et al (1990) Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms. Endocrinology 127:126–132PubMedCrossRef

27.

Kubota N, Terauchi Y, Tobe K et al (2004) Insulin receptor substrate 2 plays a crucial role in beta cells and the hypothalamus. J Clin Invest 114:917–927PubMedCentralPubMedCrossRef

28.

Matsui J, Terauchi Y, Kubota N et al (2004) Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-gamma-deficient mice on a high-fat diet. Diabetes 53:2844–2854PubMedCrossRef

29.

Kikuchi O, Kobayashi M, Amano K et al (2012) FoxO1 gain of function in the pancreas causes glucose intolerance, polycystic pancreas, and islet hypervascularization. PLoS One 7:e32249PubMedCentralPubMedCrossRef

30.

Norton L, Fourcaudot M, Abdul-Ghani MA et al (2011) Chromatin occupancy of transcription factor 7-like 2 (TCF7L2) and its role in hepatic glucose metabolism. Diabetologia 54:3132–3142PubMedCrossRef

31.

da Silva XG, Mondragon A, Sun G et al (2012) Abnormal glucose tolerance and insulin secretion in pancreas-specific Tcf7l2-null mice. Diabetologia 55:2667–2676CrossRef

32.

Kaneto H, Matsuoka TA, Kawashima S et al (2009) Role of MafA in pancreatic beta-cells. Adv Drug Deliv Rev 61:489–496PubMedCrossRef

33.

Hang Y, Stein R (2011) MafA and MafB activity in pancreatic beta cells. Trends Endocrinol Metab 22:364–373PubMedCentralPubMedCrossRef

34.

Osmark P, Hansson O, Jonsson A, Ronn T, Groop L, Renstrom E (2009) Unique splicing pattern of the TCF7L2 gene in human pancreatic islets. Diabetologia 52:850–854PubMedCrossRef

35.

Le Bacquer O, Shu L, Marchand M et al (2011) TCF7L2 splice variants have distinct effects on beta-cell turnover and function. Hum Mol Genet 20:1906–1915PubMedCrossRef

36.

Locke JM, Da Silva XG, Rutter GA, Harries LW (2011) An alternative polyadenylation signal in TCF7L2 generates isoforms that inhibit T cell factor/lymphoid-enhancer factor (TCF/LEF)-dependent target genes. Diabetologia 54:3078–3082PubMedCentralPubMedCrossRef

37.

Mao CD, Byers SW (2011) Cell-context dependent TCF/LEF expression and function: alternative tales of repression, de-repression and activation potentials. Crit Rev Eukaryot Gene Expr 21:207–236PubMedCentralPubMedCrossRef

38.

Columbus J, Chiang Y, Shao W et al (2010) Insulin treatment and high-fat diet feeding reduces the expression of three Tcf genes in rodent pancreas. J Endocrinol 207:77–86PubMedCrossRef

39.

Savic D, Ye H, Aneas I, Park SY, Bell GI, Nobrega MA (2011) Alterations in TCF7L2 expression define its role as a key regulator of glucose metabolism. Genome Res 21:1417–1425PubMedCrossRef

40.

Yang H, Li Q, Lee JH, Shu Y (2012) Reduction in Tcf7l2 expression decreases diabetic susceptibility in mice. Int J Biol Sci 8:791–801PubMedCentralPubMedCrossRef

41.

Oh KJ, Park J, Kim SS, Oh H, Choi CS, Koo SH (2012) TCF7L2 modulates glucose homeostasis by regulating CREB- and FoxO1-dependent transcriptional pathway in the liver. PLoS Genet 8:e1002986PubMedCentralPubMedCrossRef

42.

Shao W, Wang D, Chiang YT et al (2013) The Wnt signaling pathway effector TCF7L2 controls gut and brain proglucagon gene expression and glucose homeostasis. Diabetes 62:789–800PubMedCrossRef

43.

da Silva XG, Bellomo EA, McGinty JA, French PM, Rutter GA (2013) Animal models of GWAS-identified type 2 diabetes genes. J Diabetes Res 2013:906590

44.

Merrill BJ, Pasolli HA, Polak L et al (2004) Tcf3: a transcriptional regulator of axis induction in the early embryo. Development 131:263–274PubMedCrossRef

45.

Liu Z, Habener JF (2008) Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. J Biol Chem 283:8723–8735PubMedCrossRef

46.

Ueki K, Okada T, Hu J et al (2006) Total insulin and IGF-I resistance in pancreatic beta cells causes overt diabetes. Nat Genet 38:583–588PubMedCrossRef

47.

Hashimoto N, Kido Y, Uchida T et al (2006) Ablation of PDK1 in pancreatic beta cells induces diabetes as a result of loss of beta cell mass. Nat Genet 38:589–593PubMedCrossRef

48.

Knop FK (2010) Comment on: Villareal et al (2009) TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes 59:479–485. Diabetes 59:e4; author reply e5-6

49.

Gaulton KJ, Nammo T, Pasquali L et al (2010) A map of open chromatin in human pancreatic islets. Nat Genet 42:255–259PubMedCentralPubMedCrossRef

50.

Shu L, Matveyenko AV, Kerr-Conte J, Cho JH, McIntosh CH, Maedler K (2009) Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. Hum Mol Genet 18:2388–2399PubMedCrossRef

Titel: TCF7L2 in mouse pancreatic beta cells plays a crucial role in glucose homeostasis by regulating beta cell mass
verfasst von: Iseki Takamoto
Naoto Kubota
Keizo Nakaya
Katsuyoshi Kumagai
Shinji Hashimoto
Tetsuya Kubota
Mariko Inoue
Eiji Kajiwara
Hisayuki Katsuyama
Atsushi Obata
Yoshitaka Sakurai
Masahiko Iwamoto
Tadahiro Kitamura
Kohjiro Ueki
Takashi Kadowaki
Publikationsdatum: 01.03.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Diabetologia / Ausgabe 3/2014
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-013-3131-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2014

β-Arrestin2 plays a key role in the modulation of the pancreatic beta cell mass in mice

Is there a role for the adaptive immune system in pancreatic beta cell failure in type 2 diabetes?

Role for sterol regulatory element binding protein-1c activation in mediating skeletal muscle insulin resistance via repression of rat insulin receptor substrate-1 transcription

Reduction of non-esterified fatty acids improves insulin sensitivity and lowers oxidative stress, but fails to restore oxidative capacity in type 2 diabetes: a randomised clinical trial

Detection of enterovirus in the islet cells of patients with type 1 diabetes: what do we learn from immunohistochemistry? Reply to Hansson SF, Korsgren S, Pontén F et al [letter]